Biotech Values

[DewDiligence]

“It is extremely chilling if, after spending a huge sum of money, time and effort to get a drug through FDA approval, you'll then have to go through it all again to see if CMS [Medicare] will pay for it,” said Allen S. Lichter, head of the American Society of Clinical Oncology.

It may be chilling, but this is exactly how the game is played in most of the world including, notably, the major countries of Europe.